Logo, Madera BioSciences

Small Molecule Therapeutics for Alzheimer's


To develop effective, orally bioavailable, small molecule therapeutics to treat Alzheimer's disease in its very early stages modifying the natural course of the disease.

Madera is prosecuting small molecule programs seeking to increase the levels of functional, lipidated ApoE in the brain.  Literature studies define an isoform-specific role for ApoE in Aβ clearance and aggregation, and link the change in function of ApoE4 to the pathogenesis of Alzheimer’s disease. Elevated levels and/or disease-implicated

Woman Using Microscope

forms of Aβ lead to Aβ-induced neuroinflammation as a key component of Alzheimer’s disease pathology. In addition, ApoE function correlates with other neuropathological changes in Alzheimer’s disease some of which are Aβ-independent.

Our Work

We are currently developing drug-like molecules that potentiate the expression and function of ApoE via engagement of a novel biological target. 

Increasing the levels and function of ApoE aids in the clearance of Aβ from the CNS correcting a key imbalance in the early stages of Alzheimer’s disease.  Additionally, enhanced ApoE function may ameliorate certain Aβ-independent neuropathological changes characteristic of dementia.

Read More About Our Strategy Here